Nalu Medical, a Carlsbad, CA-based private company focused on innovative, minimally invasive, and non-pharmacologic solutions for chronic neuropathic pain, announced the closing of an incremental $20M in equity in Series E funding from new investor B Capital.

Nalu Medical是一家总部位于加利福尼亚州卡尔斯巴德的私人公司，专注于慢性神经性疼痛的创新，微创和非药物解决方案，宣布关闭新投资者B Capital提供的E系列股权增加2000万美元。

The round, which brought the total amount to $85M was led by Novo Holdings with $65M of the total closing in late-December 2023. Also participating in the round were all existing investors Gilde Healthcare, MVM Partners, Endeavour Vision, Decheng Capital, Longitude Capital, Advent Life Sciences, Pura Vida, and Aperture Venture Partners.

这轮交易的总金额达到8500万美元，由Novo Holdings牵头，在2023年12月下旬的总成交额中占6500万美元。所有现有投资者Gilde Healthcare、MVM Partners、Endeavor Vision、Decheng Capital、Longitude Capital、Advent Life Sciences、Pura Vida和Aperture Venture Partners也参与了这轮投资。

The company intends to use the funds to accelerate commercial growth, expand clinical and health-economic evidence, continue product development, and scale operations.

该公司打算利用这些资金加速商业增长，扩大临床和健康经济证据，继续产品开发和规模经营。

Led by President and CEO Tom West, Nalu is a medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic neuropathic pain. The Nalu Neurostimulation System delivers gentle electrical pulses to the nervous system to modulate pain signals before they get to the brain.

在总裁兼首席执行官汤姆·韦斯特（TomWest）的带领下，Nalu是一家医疗技术公司，专注于为慢性神经性疼痛患者开发和商业化创新和微创解决方案。Nalu神经刺激系统在疼痛信号到达大脑之前向神经系统传递温和的电脉冲，以调节疼痛信号。

It was designed to address major unmet needs in the treatment of chronic neuropathic pain and provide a differentiated value proposition for patients and physicians.

它旨在解决慢性神经性疼痛治疗中未满足的主要需求，并为患者和医生提供差异化的价值主张。